(Q46040062)

English

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.

scientific article published on 22 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

1 reference

based on heuristic

author name string

Nao Kurashige

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Naoki Hiramatsu

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Kazuyoshi Ohkawa

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Takayuki Yakushijin

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Shinichi Kiso

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Tatsuya Kanto

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Tetsuo Takehara

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Akinori Kasahara

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Yoshinori Doi

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Akira Yamada

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Masahide Oshita

11

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Eiji Mita

12

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Hideki Hagiwara

13

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Toshihiko Nagase

14

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Harumasa Yoshihara

15

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Eijiro Hayashi

16

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Yasuharu Imai

17

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Michio Kato

18

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Takeshi Kashihara

19

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Norio Hayashi

20

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

publication date

22 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

44

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

601-607

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on diagnosis, management, and prevention of hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Type B fulminant hepatitis is closely associated with a highly mutated hepatitis B virus strain

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19387534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-009-0038-6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19387534

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46040062&oldid=1584890072"